



**EP PerMed**

European Partnership  
for **Personalised Medicine**

## **EP PerMed Twinning Call 2026**

# Advancing Collaborative Implementation of Personalised Medicine Approaches in Healthcare

Call for Proposals

10.12.2025

EIT Health



**Co-funded by  
the European Union**

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

## Change Log

---

The EP PerMed Twinning Call 2026 was published on 10 December 2025. Any changes implemented after this date will be tracked below. If no information is included, it means no changes have been made since the launch of the Call.

Date	Description of Change	Location in the document

## Introduction and aims of EP PerMed

---

Personalised Medicine (PM) represents a paradigm shift from a “one size fits all” approach to an optimised strategy for the prevention, diagnosis and treatment of disease for each individual, based on their unique characteristics, including biological features (e.g., phenotype, endotype, genotype), as well as lifestyle and environmental factors. Accordingly, PM puts the patient at the very centre of healthcare, aiming for optimised health promotion, treatments and management of disease or determination of a predisposition to disease. The field of PM has been advancing rapidly, and the range of technologies, methodologies and information utilised is much broader, supporting improved healthcare, diagnostics and tailor-made treatments, including rehabilitation, and prevention strategies.

The European Partnership for Personalised Medicine, EP PerMed, is a platform for joint programming of national and European regional research and innovation (R&I) programmes putting into action “The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023)”<sup>1</sup>, SRIA for PM (2023), through dedicated research, development and innovation funding.

The vision of the European Partnership for Personalised Medicine is to improve health outcomes within sustainable healthcare systems through research, development, innovation and implementation of personalised medicine approaches for the benefit of patients, citizens, and society.

---

<sup>1</sup> *Strategic Research & Innovation Agenda for Personalised Medicine (2024) European Partnership for Personalised Medicine - EP PerMed.*  
Available at: <https://www.eppermed.eu/action-areas/sria/> (Accessed: 05 December 2024).

## Definition of Personalised Medicine

---

*EP PerMed adheres to the definition stated in the PerMed SRIA: 'Shaping Europe's Vision for Personalised Medicine' (2015), adopted from the Horizon2020 Advisory Group:*

*"Personalised Medicine refers to a medical model using characterisation of individuals' phenotypes and genotypes (e.g., molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention."*

*Some additional information can be found in the 2018–2020 Advice of the Horizon 2020 Advisory Group for Societal Challenge 1, "Health, Demographic Change and Well-being":*

*"Different synonymous terms have been used alongside 'personalised medicine', most commonly 'precision medicine' and 'stratified medicine'. While there may be subtle differences in the literal meanings of these terms, they usually refer to the same concept when applied in practice. Stratified medicine (mainly used in the UK) is more treatment-dependent, while precision medicine (mostly used in US) has a relatively broad meaning as it refers to 4P (predictive, preventive, personalised and participatory) medicine. We use the term personalised medicine because this term best reflects the goal of effectively tailoring treatment based on an individual's 'personal profile', as determined by the individual's genotype and phenotype data. Based on individuals' profiles, PM aims to identify the optimal treatment regime by avoiding the treatment-failure approach commonly used in current evidence-based medicine."*

## Programme Timeline

---

<b>Date</b>	<b>Event</b>
<b>13 October 2025 – 26 February 2026</b>	<u>Online matchmaking period</u>
<b>10 December 2025</b>	Opening of the Call for Proposals submission
<b>17 December 2025 at 12:00 CET</b>	<u>Call information webinar</u>
<b>15 January 2026</b>	<u>Online matchmaking event</u>
<b>26 February 2026 at 16:00 CET</b>	Deadline for proposals submissions
<b>27 February – 20 March 2026</b>	Eligibility check
<b>23 March 2026</b>	Notification of eligibility check outcome and invite to online pitching sessions
<b>14 – 21 April 2026</b>	Online pitching sessions
<b>06 May 2026</b>	Final Results notification
<b>06 May – 08 June</b>	Stand still period
<b>Week beginning 08 June 2026</b>	Kick off meeting
	Onboarding and contracting begins

---

## Objectives & Scope

---

### Background

This Twinning Call is designed to accelerate the implementation of personalised medicine (PM) solutions or approaches from one country to another through peer-to-peer exchanges.

A 'Twinning' is a structured partnership where a 'Twinning Donor' with an innovative solution or approach, shares its expertise in this innovative solution or approach with another party called the 'Twinning Receiver'. The goal of this Twinning is to implement the solution or approach being shared into the respective institution/organisation/company of the Twinning Receiver.

The desired impact of any such Twinning is to support capacity building and the adoption of innovative solutions and practices into national health systems.

This Twinning Call offers a funding mechanism to facilitate the transnational transfer and implementation of PM approaches from one Horizon Europe country to another.<sup>2</sup>

### Call summary

This Call offers up to 50,000 EUR per Twinning partnership to activities that facilitate the exchange of solutions or approaches in Personalised Medicine and build up the capacities and capabilities of one or both participating parties. Twinning partnerships should last between 6 and 12 months.

Here we define and explain the twinning concept including the definition of the "donor" and "recipient".

EP PerMed is not specifying what should be exchanged in the "Twinning" process and is open to receiving eligible applications that cover a range of different PM approaches and disease areas.

Examples of what could be exchanged may cover:<sup>3</sup>

- Implementation of a specific care pathway in PM or defined PM approach within the Twinning Receiver's organization, following a model that has already been effectively established by the Twinning Donor in its own organization.
- Implementation of a specific technological solution in PM within the Twinning Receiver's organization, based on a PM solution that has already been successfully deployed by the Twinning Donor in its own organization.

---

<sup>2</sup> Countries participating in Horizon Europe include all EU Member State plus Third Countries associated with Horizon Europe. See here for a list of all Horizon Europe Associated Third Countries - [https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation-horizon-euratom\\_en.pdf](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation-horizon-euratom_en.pdf)

<sup>3</sup> This list is non-exhaustive, other Twinning activities not listed here may also be considered.

- This Call will not award funding to projects that aim at exchanging knowledge about what PM is in general or for pure research purposes. PM solutions and twinning concepts proposed must have a clear direct or indirect impact on patient care.

	Description
<b>Objective</b>	<p>Share knowledge, concepts and skills on a particular PM solution or approach from a Twinning <b>Donor</b> to one or two Twinning <b>Receiver(s)</b>.</p> <p>By the end of the project, the Twinning Receiver(s) should be able to initiate actions towards, adapt, partially adopt or fully adopt the PM solution or approach being exchanged.</p>
<b>Expected Outcome</b>	The Twinning Receiver(s) develops and applies the PM solution or approach being exchanged within their own local settings. By the end of the Twinning the solution or approach being exchanged should continue to be implemented and should become a part of the healthcare institution's patient service offered.
<b>Scope of the Activities</b>	<p>The Twinning Call will pair at least two and up to three institutions together. One institution/organisation/company will be the Donor, and the other up to two institution(s) will be the Receiver(s). The Donor institution is responsible for sharing its experience, knowledge, and practices relevant to the specific PM solution or approach with the Receiver organisation(s).</p> <p>The partnership must cross borders and cover at least two and up to three Horizon Europe countries.</p> <p>Twinning partnerships should enable the Twinning Receiver(s) institution to:</p> <ul style="list-style-type: none"> <li>• Initiate implementation of a defined PM solution or approach with support</li> <li>• Adapt a PM solution or approach</li> <li>• Partially adopt a PM solution or approach</li> <li>• Fully adopt or acquire a solution or approach</li> </ul>
<b>Grant Duration</b>	Maximum 12 months from the award notification date.
<b>Number of selected projects</b>	Up to 6 Twinning partnerships will be funded.

<b>Funding</b>	A maximum grant amount of 50,000 EUR (incl. overhead) can be allocated to individual Twinning partnerships (projects).
----------------	--

## Types of initiatives to be selected

The Twinning Partnerships are aimed at local, regional and national health and care providers legally registered in a participating Horizon Europe country that wish to adopt PM solutions that are transferable from one provider to another.

Activities must demonstrate their link to PM and may cover the whole health value chain: diagnosis, theranostics, prevention strategies, screening, early detection, and diagnostic tools, new personalised treatments, interventions and patient management, recovery and follow-up support systems. The proposed twinning concepts must have a clear direct or indirect impact on patient care.

Activities that **will not be funded** and are out of scope include:

- Any technological solution that is below Technology Readiness Level (TRL) 9.<sup>4</sup> TRL 9 is the top of the TRL scale and signifies that a technology has been successfully tested in an operational environment and is ready for full deployment. At TRL 9 the solution has undergone extensive validation and demonstrated its functionality in real-world conditions, is no longer a prototype but a fully developed and commercially viable product.
- Policy level interventions.
- Regulatory or ethical policies or guidelines.
- Public awareness campaigns.
- Preliminary groundwork that does not progress into initial execution phases.
- Twinning partnerships that are mainly profit-oriented, mainly for marketing purposes of a commercially available product or only aim at exchanging information about PM or PM approaches, with no prospects of PM implementation in health and care institutions.

---

<sup>4</sup> Horizon Europe definition of Technology Readiness Level (page 14) - [https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes\\_horizon-2023-2024\\_en.pdf](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf)

## How to apply

---

Applicants must submit their proposals via the Application Platform:

<https://apply.eithealth.eu/> Please follow the instructions to complete account registration. If you have any questions, please see the “Guide for applicants” or contact [calls\\_eppermed@eithealth.eu](mailto:calls_eppermed@eithealth.eu).

Applicants will need to complete a work plan and the project budget using the template provided. The budget template will be made available on the application platform and is also available [here](#) (this link will launch a download of the budget template into your browser’s downloads folder). For more information on how the work plan and project budget link to funding and grant payout please see the section on **Funding and Sub-Grant Payout**.

## Eligibility criteria

---

### 1) General Conditions

Applications must meet all the below eligibility criteria to be invited to the independent expert evaluation stage. Each application will be reviewed for these eligibility criteria by the Call Secretariat - EIT Health, and members of the EP PerMed consortium.

- Applicants must submit their proposal via the application platform before the deadline on **26 February 2026 at 16:00 CET**.
- Applications must be written in English.
- The Twinning language is English, and the project grant agreement (PGA) must be signed between EP PerMed and all parties in the application consortium in its English version.
- Applications must be submitted in English.
- Twinning activities must be carried out in English.
- Applications can request a maximum of 50,000 EUR of funding including overheads.
- Applicants must use and upload any templates requested and provided in the application platform. Applications that upload the incorrect template or a modified version of the template will be considered ineligible.
- To be eligible for funding, all applicants must be legally registered in a Horizon Europe country or associated country.
- The PM solution or approach must be mature for implementation. In the case of technological solutions this means TRL 9 and CE-marked if required.
- Application must meet the definition of PM as defined in this call. See [Definition of Personalised Medicine](#) on page 4.
- Partners (Beneficiaries/Affiliated Entities/Associated Partners) within the EP PerMed consortium are not eligible for this Call.
- Individuals are not eligible for this Call.

## 2) Specific Conditions

### 2.1) Consortium Eligibility

Applicants are encouraged to use the dedicated **Matchmaking platform** to fulfil the consortium composition requirements. A dedicated online matchmaking event on 15 January 2025 will also be held for interested applicants. See section **Online Webinar** for more information.

The following conditions apply to the composition of consortia:

- A consortium submitting an application must include one Donor organisation, and at least one, but not more than two Receiver organisations.
- The consortium must be transnational, involving a minimum of two and a maximum of three organisations legally registered in at least two different EU Member State countries or countries associated to Horizon Europe.
- Consortium members must be legally and financially independent of each other.
- Proposals must be submitted by applicants belonging to one of the following categories:
- Twinning Donor organisations: local, regional and national health and care providers established in an EU Member State or country associated with Horizon Europe with a PM solution or approach available for transfer.
- Twinning Receiver organisations: local, regional and national health and care providers established in an EU Member State or country associated with Horizon Europe that wish to adopt the Twinning Donor organization's PM solution or approach.
- The consortium must be completed at the time of submission.

### 2.2) Roles in the consortium

- **Application Lead**  
The application lead will serve as the representative of the consortium and will be the primary contact person on behalf of the consortium for communication with EP PerMed. The application lead must ensure all relevant information is communicated to the co-applicants. The application lead is also responsible for submitting both the interim (DEL 01) and final report (DEL 02) of the Twinning partnership.
- **Co-applicants**  
The activities of the Twinning partnership should be designed and organised in collaboration between the application lead and the co-applicants. Applications should cover the Twinning partnership strategy, an operational and logistics plan

activity, a communications plan, and a financial plan. The division of this work should be agreed between all applicants.

### 2.3) Eligible costs and project duration

- The types of activities that may be awarded funding include hosting meetings or working groups, travel expenses, or fees for professional services.<sup>5</sup>
- Costs for the further development of PM solutions are not eligible.
- Costs for devices, instruments and equipment are not eligible.
- Funding will support the Twinning activity up to the submission of the final activity report, which must be delivered no later than 6 May 2027.

## Evaluation process and criteria

---

Applications will first be reviewed for eligibility against the criteria in the **Eligibility Check** section above by EP PerMed. Eligible applications will then be assessed and scored by an independent panel of experts following the evaluation criteria below.

### 1) Eligibility check

The minimum requirements for applying, including eligibility criteria, are specified in **Eligibility Check** section above.

An eligibility check will be performed to validate the application's compliance with the requirements outlined in this Call. This will yield a yes/no decision on whether submitted proposals are eligible and can progress to the next evaluation stage.

### 2) Online Pitching

All eligible applications will be invited to present their proposals at an online pitch. This will involve a presentation of the proposal by applicants in front of a panel of independent experts and will be followed by a question and answers session. Details on the organisation of the pitches will be communicated to eligible applicants following the eligibility check. Applicants must ensure their availability for pitches according to the **Programme Timeline**. Specific times of individual pitches will be communicated when the notification of eligibility is sent.

---

<sup>5</sup> This list is non-exhaustive

Each proposal will be sent to three external independent evaluators in advance of the pitches so they can read applications. Following the online pitches, experts will score each application based on a scale of 1-100 points. An application's final score will be the average of the three expert's individual scores.

Only projects that get a final score of at least 70 / 100 will be considered for funding. The top ranked applications will be selected for funding.

Please see section below on **Evaluation Criteria** for details on the evaluation criteria that projects will be assessed against during the online pitches.

### 3) Ethical, Legal, and Social Issues (ELSI) review

As part of the application process applicants will be asked to complete a Ethical, Legal, and Social Issues (ELSI) questionnaire. This is a self-assessment of the proposal in the area of ethics, legal, and social issues. All applications shortlisted for award will have their self-assessment questionnaire sent to experts for review. This process reviews any ethical, legal and social issues in the application, and makes recommendations for amendments to the project where necessary, thereby helping to de-risk the EP PerMed portfolio.

## Evaluation criteria

---

The evaluation criteria for the EP PerMed Twinning Call are as follows:

Area	Criteria	Weight
<b>Excellence</b>	<ul style="list-style-type: none"> <li>Alignment with the Call scope, objectives, and intended outcome.</li> <li>Alignment with the definition of personalised medicine used by EP PerMed</li> <li>Maturity of offering by the Twinning Donor</li> </ul>	35%
<b>Impact</b>	<ul style="list-style-type: none"> <li>Value of benefits for the Twinning Receiver(s)' patients, citizens, organisation and / or healthcare system(s)</li> <li>Potential for upscaling after the Twinning project is completed</li> </ul>	40%
<b>Implementation</b>	<ul style="list-style-type: none"> <li>Quality and completeness of the work-plan, detail of task and result descriptions</li> <li>Feasibility of the work plan to meet the objectives specified.</li> <li>Feasibility of the budget to meet the objectives specified.</li> <li>Capacity each participant in the consortium to deliver.</li> <li>Consortium expertise.</li> </ul>	15%
<b>Pitch quality</b>	<ul style="list-style-type: none"> <li>Clarity of pitch presentation content and style</li> <li>Quality of pitch presentation content and style</li> </ul>	10%

## Funding and subgrant payout

Funding available per Twinning awarded project is up to 50,000 EUR (fifty thousand Euros) including overheads. Reimbursement rate is 100%.

Funding will be provided through a lump sum contract, structured to ensure efficient and effective use of resources. You can learn more about lump sum budgets on the European Commission Funding and Tenders page [here](#).

To define and justify the project budget, each team will need to provide a detailed budget table with cost estimations during application using the template provided. The template will be available on the application platform, and also [here](#) (note this link will trigger a download directly into your browser's "Downloads" folder).

Guidance for applicants on making lump sum submissions can be found [here](#). Your project should consist of **a single work package**, with all relevant tasks and costs sitting under this single work package. The budget costs must be an approximation of the actual costs and meet the eligibility criteria of Horizon Europe. The costs provided in the budget will be the costs included in the grant agreements in the case of a successful application.

Applications that do not use the provided template will be considered ineligible and will not proceed to the external evaluation stage.

With budgets structured as **a single work package** payment will be distributed in two instalments:

1. An initial pre-financing payment of 50% of the total funding will be made at the start of the project, tied to the completion of the contracting phase.
2. The remaining 50% will be disbursed upon approval of the interim and final activity report, which will verify the completion of the activity and the achievement of the project's objectives.

Payment	Amount	Description	Mandatory Conditions
<b>Pre-financing</b>	50%	Onboarding and kick-off.	Completion of contracting phase.
<b>Final payment</b>	50%	Completion of the interim report at 6 months post award (DEL 01). Completion of the final activity report at 12 months post award (DEL 02).	Completion of the task and the Project's objectives. Completion of the interim and final activity reports on the indicated timelines.

## Required Deliverables

The table below summarises the expectations from the Twinning Partnerships, based on a duration of 12 months.

Selected consortia must commit to the timelines as outlined in the [Programme Timeline](#).

Expected Deliverables	Detail
<b>Milestones</b>	<ul style="list-style-type: none"> <li>MS 01: At least one documented physical visit of the Twinning consortium to the Donor or Receiver's Institution.</li> <li>MS 02: Presentation of the Twinning results at a dedicated event (online or in person) at the end of the project. PowerPoint slides and evidence of attendance of the event will serve as evidence.</li> </ul>
<b>Deliverables</b>	<ul style="list-style-type: none"> <li>DEL 01: Twinning interim report (and publishable interim summary), which must be delivered no later than 16 October 2026, based on a report template with specific questions and format, to be provided in advance.</li> <li>DEL 02: Twinning final activity report and final publishable summary, which must be delivered no later than 16 April 2027. The activity report must use the report template and answer specific questions which will be provided in advance.</li> </ul>

### Criteria for final deliverables

Final payment will be based on the submission of the two deliverables. Each deliverable will need to be signed off by the Call Secretariat - EIT Health, to receive the final payment. The below table sets out the minimum criteria that deliverables must meet to receive sign off, and final payment be released.

Expected Deliverables	Minimum criteria for sign off
DEL 01: Completion of the interim Twinning report	<p>The interim report must include:</p> <ul style="list-style-type: none"> <li>Full participant list of the consortium</li> <li>Overview of completed activities/meetings/workshops of the Twinning workplan and planned future activities/meetings/workshops per work package</li> <li>Overview of completed or planned physical (at least one) visits to the Twinning Donor or Receiver's Institution</li> <li>Main Twinning Outputs/Results</li> </ul> <p>The interim report must be:</p> <ul style="list-style-type: none"> <li>Detailed and complete at the indicated timelines.</li> <li>Reviewed and agreed by the consortia and communicated to the EP PerMed team on time.</li> </ul>

Expected Deliverables	Minimum criteria for sign off
DEL 02: Completion of the final Twinning report	<p>The final report must include:</p> <ul style="list-style-type: none"> <li>• Full participants' list of the consortium (including updates)</li> <li>• Overview of completed activities/meetings/workshops of the Twinning workplan.</li> <li>• Overview of completed physical (at least one) visits to the Twinning Donor or Receiver's Institution.</li> <li>• Main Twinning Outputs/Results</li> <li>• Lessons Learned and Experiences</li> </ul> <p>The final report must be:</p> <ul style="list-style-type: none"> <li>• Detailed and complete at the indicated timelines.</li> <li>• Reviewed and agreed by the consortia and communicated to the EP PerMed team on time.</li> </ul>

## Conflicts of interest

---

The EP PerMed Twinning Call is committed to maintaining the highest standards of confidentiality and managing conflicts of interest throughout the applications and selection process.

All applications submitted through the application platform are accessible only to applicants and selected staff working in the EP PerMed partnership who have responsibilities for processing applications. Materials and information provided by applicants will be treated as strictly confidential. Members of the EP PerMed Consortium, EIT Health (the Call Secretariat), and independent evaluators are required to sign confidentiality agreements, ensuring that sensitive information is not disclosed to unauthorised parties.

During the selection process, applications and its attached contents are shared with assigned external evaluators, who are contractually bound to confidentiality. Evaluators and the Call Secretariat - EIT Health, involved in the selection process are required to declare any potential conflicts of interest. Any evaluator with a conflict of interest will be prevented from assessing the relevant application and replaced with another evaluator who has no conflict to ensure an unbiased review. This commitment to confidentiality and conflict of interest management guarantees a fair and transparent selection process, fostering trust and integrity within the programme.

Member organisations of the EP PerMed consortium are not eligible to apply to this Call.

Applicants and potential beneficiaries of the grant in selected activities must avoid any conflict of interest and comply with the principles of transparency, non-discrimination, and sound financial management.<sup>6</sup>

<sup>6</sup> Regulation EU 2021/695, <https://eur-lex.europa.eu/eli/req/2021/695/oj/eng>

## Redress procedure

---

Applicants can appeal against the final award decision if they suspect a breach in the evaluation and selection procedures. This redress procedure only covers the procedural aspects of the Call. The redress will not call into question the scientific or technical judgement of experts/evaluators.

Applicants should submit their appeal to the Call Secretariat - EIT Health, via email to [appeals@eithealth.eu](mailto:appeals@eithealth.eu) within seven calendar days following notification of the application outcome. The outcome notification email containing the results of the evaluation will give information on the appeals procedure, which is described below.

### Admissibility of appeals

For an appeal to be admissible the following conditions must be met:

- The appeal must be submitted by the team to which the appeal relates;
- Only one appeal per proposal will be considered;
- The appeal must be submitted via email within seven calendar days of the outcome notification email. The appeal must contain the following minimum information:
  - The name of the Call for Proposals;
  - The proposal acronym;
  - The title of the proposal;
  - A description of the alleged shortcomings of the evaluation procedure.

The appeal must demonstrate a procedural irregularity, factual error, manifest error of assessment, misuse of powers, or a conflict of interests. Appeals that do not meet the above conditions, or do not deal with the evaluation of a specific proposal, or express mere disagreement with the result or the reasoning of the evaluation may be judged as not suitable for redress.

### Procedure

Upon receipt of an appeal, an acknowledgement of receipt will be sent from [appeals@eithealth.eu](mailto:appeals@eithealth.eu) within seven calendar days. The acknowledgement shall report the redress process and the anticipated date by which a decision on the appeal will be communicated to the appellant.

All appeals received within the seven calendar days deadline will be processed together. The decision will be communicated to the appellant within two weeks from the deadline for submitting the appeals.

## **Online webinar and Call contact information**

---

### **Matchmaking Platform – opening on Monday 13 October, closing on Thursday 26 February**

Join the dedicated Matchmaking platform to list your organisation as a Twinning Donor or Twinning Receiver and find twinning partners. Link to the matchmaking platform:

<https://www.b2match.com/e/online-matchmaking-ep-permed-twinning>

### **Call information Webinar – Wednesday 17 December 2025, 12.00 to 13.00 CET**

Register [here](#) to join an online webinar to hear more about the call and ask questions.

### **Online matchmaking event – 15 January 2026, 12.00 to 14.00 CET**

Register [here](#) to join an online matchmaking event to help you find twinning partners. Interested Twinning Donor and Receiver organisations will present their successful PM approaches or PM needs in the form of a pitch to further facilitate the Twinning partnership matchmaking process.

For speakers interested to pitch their PM solution or need: Please complete [this form](#) to express your interest to pitch.

For further information:

Please visit the [EP PerMed website](#) contact: [calls.eppermed@eithealth.eu](mailto:calls.eppermed@eithealth.eu). When emailing, please pre-fix the email subject with “EP PerMed\_Twinning” and your application code, for example “EP PerMed\_Twinning: EPTwin-2025-12345”. This will ensure the right people pick up your email.